If you invested $5,000 in this ASX pharmaceuticals stock a year ago, you'd have $34,711 now!

Just how lucky have investors been with this stock?

| More on:
Woman looks amazed and shocked as she looks at her laptop.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's an interesting thing to look back on an ASX stock that you don't own and see a giant that you wish you did own. For one, it usually leads to that sense of regret of not finding that winner sooner, of missing out on the incredible windfall gains that it has showered on to its lucky investors. But it can also renew our resolve to invest in ASX stocks and find the inevitable next winner.

That's what all investors have to confront today when it comes to the Clarity Pharmaceuticals Ltd (ASX: CU6) share price.

This ASX pharmaceutical stock has been an unbridled winner for ASX investors over the past 12 months. A year ago, shares of this company were going for just 88 cents each. Today, those same shares are currently trading for $6.11.

Now that might be down a chunky 2.7% for the day thus far. But Clarity shares still remain up an incredible 594% from where they were this time in 2023.

If it weren't for a rough July so far, this ASX pharmaceuticals stock would be up even higher. As my Fool colleague Bronwyn covered earlier this month, Clarity actually topped out the entire All Ordinaries Index (ASX: XAO) over the 2024 financial year.

This company's shares returned a massive 674.29% over the 12 months to 30 June 2024, rising from 70 cents a share at the start of July 2023 to $5.42 when the markets closed at the end of June.

Despite Clarity's FY2024 success, most of this ASX pharmaceuticals stock's gains came in the back half of the year. In April, to be specific.

Clinical trials behind ASX pharmaceuticals stock's explosive growth

April was the month that Clarity revealed that a prostate cancer patient had a "complete response" to two cycles of Clarity's 67Cu-SAR-bisPSMA treatment, with the patient showing no detectable levels of cancer in the six months following the treatment.

Investors welcomed Clarity's subsequent capital raising, and the ASX pharmaceuticals stock hasn't looked back since.

But let's get down to just how much long-term Clarity investors have banked from this company's gains.

Let's assume our investor managed to spend $5,000 on Clarity shares 12 months ago. As we've established, back on 24 July (22 July last year was a Saturday), Clarity shares closed at 88 cents each. If one had spent $5,000 on this ASX pharmaceuticals stock back then, one would have been able to buy themselves 5,681 shares with some change left over.

If that investor held those 5,681 shares until today, they would be sitting on a Clarity holding worth $34,711 right now. Eat your heart out.

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should you buy the dip on the CSL share price?

Has the market sell-off created an opportunity to buy this mega ASX 200 blue chip at an attractive price?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Up 136% in a year, why is this ASX 200 share slipping on Wednesday?

The high-performing ASX 200 share is expanding its product pipeline.

Read more »

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Healthcare Shares

Meet the dirt cheap ASX 200 stock that could rocket 75%

Bell Potter thinks investors should be snapping up this stock while it is down in the dumps.

Read more »

A man in a white coat holds a laptop in one hand and his head in the other, it's bad news.
Healthcare Shares

This ASX 200 healthcare share is sinking 9% on CEO exit

Investors are selling off this stock on Tuesday. Here's what you need to know.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Why is the CSL share price falling on Monday?

The ASX 200 biotech stock has lost 9% of its value since the start of the new year.

Read more »

Health professional working on his laptop.
Healthcare Shares

Are Sonic Healthcare or CSL shares a better buy?

Which of these healthcare giants is a better buy?

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Dividend Investing

Hoping to bag the boosted dividend from CSL shares? Here's your deadline…

The ASX 200 biotech is rewarding investors with a 9% higher interim dividend this year.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

2 ASX healthcare shares rated as top buys

Are these two names healthy choices for your portfolio? Let's see.

Read more »